Rocket Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
202
- Stock Symbol
-
RCKT
- Investments
-
2
- Share Price
-
$1.97
- (As of Friday Closing)
Rocket Pharmaceuticals General Information
Description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Contact Information
Website
www.rocketpharma.comCorporate Office
- 9 Cedarbrook Drive
- Cranbury, NJ 08512
- United States
Corporate Office
- 9 Cedarbrook Drive
- Cranbury, NJ 08512
- United States
Rocket Pharmaceuticals Stock Performance
As of 20-Nov-2026, Rocket Pharmaceuticals’s stock price is $1.97. Its current market cap is $218M with 112M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.97 | $2.11 | $1.94 - $5.45 | $218M | 112M | 1.89M | -$0.15 |
Rocket Pharmaceuticals Financials Summary
As of 30-Sep-2026, Rocket Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 29,758 | 182,147 | 1,126,637 | 2,290,074 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,676) | (220,722) | (263,830) | (252,561) |
| Net Income | (16,152) | (223,123) | (258,746) | (245,595) |
| Total Assets | 419,504 | 330,449 | 527,700 | 566,341 |
| Total Debt | 55,042 | 24,877 | 25,498 | 25,042 |
Rocket Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rocket Pharmaceuticals Comparisons
Industry
Financing
Details
Rocket Pharmaceuticals Competitors (81)
One of Rocket Pharmaceuticals’s 81 competitors is Rhythm Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Vaxart | Formerly VC-backed | South San Francisco, CA | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Avalo Therapeutics | Formerly VC-backed | Wayne, PA |
Rocket Pharmaceuticals Patents
Rocket Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020237219-A1 | Gene therapy vectors for infantile malignant osteopetrosis | Inactive | 23-May-2019 | ||
| WO-2020167996-A1 | Gene therapy vectors for treatment of danon disease | Inactive | 12-Feb-2019 | ||
| US-20210198695-A1 | Production methods for viral vectors | Inactive | 16-Aug-2018 | ||
| WO-2020037249-A1 | Production methods for viral vectors | Inactive | 16-Aug-2018 | ||
| WO-2020028430-A1 | Methods for gene modification of hematopoietic cells | Inactive | 30-Jul-2018 | A61K35/28 |
Rocket Pharmaceuticals Signals
Rocket Pharmaceuticals Acquisitions (2)
Rocket Pharmaceuticals’s most recent deal was a Merger/Acquisition with Renovacor for . The deal was made on 01-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Renovacor | 01-Dec-2022 | Merger/Acquisition | Drug Discovery | ||
| Inotek Pharmaceuticals | 04-Jan-2018 | Merger/Acquisition | Drug Discovery |
Rocket Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Rocket Pharmaceuticals FAQs
-
When was Rocket Pharmaceuticals founded?
Rocket Pharmaceuticals was founded in 1999.
-
Where is Rocket Pharmaceuticals headquartered?
Rocket Pharmaceuticals is headquartered in Cranbury, NJ.
-
What is the size of Rocket Pharmaceuticals?
Rocket Pharmaceuticals has 202 total employees.
-
What industry is Rocket Pharmaceuticals in?
Rocket Pharmaceuticals’s primary industry is Biotechnology.
-
Is Rocket Pharmaceuticals a private or public company?
Rocket Pharmaceuticals is a Public company.
-
What is Rocket Pharmaceuticals’s stock symbol?
The ticker symbol for Rocket Pharmaceuticals is RCKT.
-
What is the current stock price of Rocket Pharmaceuticals?
As of 20-Nov-2026 the stock price of Rocket Pharmaceuticals is $1.97.
-
What is the current market cap of Rocket Pharmaceuticals?
The current market capitalization of Rocket Pharmaceuticals is $218M.
-
Who are Rocket Pharmaceuticals’s competitors?
Rhythm Pharmaceuticals, Vaxart, Denali Therapeutics, Alector, and Avalo Therapeutics are some of the 81 competitors of Rocket Pharmaceuticals.
-
What is Rocket Pharmaceuticals’s annual earnings per share (EPS)?
Rocket Pharmaceuticals’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process